IntrinsicIntrinsic
← All summaries

Fortive Corp

FTV
Financials & Chart →

Business Summary

Fortive Corporation operates in the essential technologies sector, focusing on keeping the world safe and productive through its two strategic segments: Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS). The company's business model revolves around designing, developing, manufacturing, and marketing products, software, and services, leveraging leading brand names, innovative technologies, and strong market positions. Fortive generates revenue from both product and software sales, as well as services, with product and software sales contributing $3,341.3 million and services contributing $817.8 million to total sales in 2025. The company serves a diverse customer base across various vertical end markets, including healthcare, industrial and manufacturing, energy and infrastructure, government, and retail.

The Intelligent Operating Solutions segment provides advanced instrumentation, software, and services to customers for mission-critical workflows. These offerings include professional instruments for maintenance, repair, measurement, and condition monitoring, facility and asset lifecycle (FAL) software applications, and connected worker safety and compliance solutions. Key brands in this segment include FLUKE, SERVICECHANNEL, GORDIAN, ACCRUENT, INDUSTRIAL SCIENTIFIC, and INTELEX. In 2025, the IOS segment generated sales of $2,856.3 million and an operating profit of $738.3 million , representing an operating profit margin of 25.8% .

The Advanced Healthcare Solutions segment delivers critical workflow solutions to healthcare providers, aiming to enhance patient care efficiency. Its offerings encompass instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. Brands within this segment include ADVANCED STERILIZATION PRODUCTS ("ASP"), CENSIS, FLUKE BIOMEDICAL, LANDAUER, and PROVATION. For 2025, the AHS segment reported sales of $1,302.8 million and an operating profit of $138.6 million , achieving an operating profit margin of 10.6% .

For the fiscal year ended December 31, 2025, Fortive reported total sales of $4,159.1 million , an increase from $4,080.9 million in 2024. Gross profit for 2025 was $2,641.1 million , with a gross profit margin of 63.5% . Operating profit stood at $720.2 million , resulting in an operating profit margin of 17.3% . Net earnings from continuing operations were $532.7 million , leading to diluted EPS from continuing operations of $1.59 . The company's cash and equivalents at year-end 2025 were $375.5 million . Total long-term debt, including the current portion, was $3,213.5 million . Operating cash flow provided by continuing operations was $1,035.7 million .

Comparing 2025 to 2024, total revenue growth (GAAP) was 1.9% . Core revenue growth (non-GAAP) was 1.7% , driven by favorable pricing of 2.2% , partially offset by a volume decline of 0.6% . The operating profit margin decreased by 30 basis points to 17.3% in 2025 from 17.6% in 2024. This was primarily due to a favorable impact of 105 basis points from pricing and productivity, offset by an unfavorable 135 basis points from other items, including incremental stock-based compensation costs related to the Separation and discrete restructuring charges. Sales in the IOS segment grew by 2.3% (GAAP) and 2.1% (core revenue) in 2025, while AHS sales grew by 1.2% (GAAP) and 0.8% (core revenue).

A significant operational development during 2025 was the completion of the separation of the Precision Technologies segment into an independent publicly-traded company, Ralliant Corporation, on June 28, 2025 . This separation was effected as a tax-free spin-off for Fortive shareholders for U.S. federal income tax purposes. In connection with this, Fortive received a cash dividend of $1.15 billion from Ralliant, which was used to repurchase common stock and repay outstanding debt, including approximately $294 million of Euro-denominated senior unsecured notes and $421 million for the Euro Term Loan and Yen Term Loan. The company also made two acquisitions in 2025, one in each segment, with aggregate cash consideration of $25.7 million .

Business Outlook

The company's financial outlook is subject to various assumptions and risks, including ongoing geopolitical events, global economic and consumer trends, monetary policies, inflationary pressures, governmental policies on international trade, regulations, sanctions, and healthcare, as well as operational challenges from tariffs and foreign exchange rate volatility. Management continues to monitor these conditions and utilize the Fortive Business System (FBS) to manage challenges through pricing, cost, and productivity actions. If exchange rates in effect as of December 31, 2025, were to prevail throughout 2026, currency exchange rates would positively impact 2026 estimated sales by approximately 0.8% relative to performance in 2025.

Fortive's growth strategy, "Fortive Accelerated," is built on three pillars: profitable organic growth acceleration powered by the amplified Fortive Business System (FBS), disciplined capital allocation, and a commitment to building investor trust. The company is making significant investments, both organically and through acquisitions, to address technological change in its markets and to improve manufacturing, research and development, and customer-facing resources. This includes incorporating new technology enablers like artificial intelligence and machine learning to drive accelerated innovation, greater commercial success, and more recurring customer value.

In terms of operational outlook, the company is focused on continuous improvement through its Fortive Business System (FBS), which is continually evolving to accelerate and sustain progress in every aspect of the business. This includes building new capabilities to drive accelerated innovation, greater commercial success, and more recurring customer value. The company has also initiated a discrete restructuring plan in the fourth quarter of 2024, which is expected to be completed by the second half of 2026, primarily involving targeted workforce reductions to realign cost structures.

Planned capital allocation includes ongoing investments in innovation, as evidenced by increased research and development (R&D) spending. R&D expenses increased year over year during both 2025 and 2024 due to ongoing investments in innovation. The company also has an active share repurchase program, with 15.5 million shares remaining authorized under the General Share Repurchase Program and $67.5 million remaining authorized under the Special Share Repurchase Program as of December 31, 2025. Dividends are currently paid quarterly at $0.06 per share . Capital expenditures are planned for increasing production capacity, replacing aged equipment, supporting product development, improving IT systems, and purchasing equipment for revenue arrangements.

Structural headwinds and execution risks management explicitly flagged include the potential for global economic slowdown, supply chain disruptions, fluctuations in commodity costs, intense competition, and the need for timely development and customer acceptance of new products. The company also faces risks related to its international operations, including economic, political, legal, and compliance factors, as well as volatility in trade relations and foreign currency exchange rates. Specific geopolitical conflicts, such as the Russian invasion of Ukraine, conflict in the Middle East, and tension between China and Taiwan, could result in sanctions, market instability, increased costs, and impact demand.

Risk Factors

Fortive faces a multitude of material risks, including adverse global economic conditions, market slowdowns, and financial market instability, which could reduce demand, increase price competition, and impair asset values. Supply chain disruptions, reliance on sole or limited suppliers, and fluctuations in commodity or component costs could lead to production interruptions, delays, increased expenses, and reduced profitability. Intense competition and the failure to timely develop and commercialize innovative products could result in decreased demand and market share. Cybersecurity threats, including breaches and cyberattacks, pose risks of operational disruption, intellectual property compromise, data privacy issues, and legal liabilities. Defects in products or services could lead to recalls, reputational damage, and product liability claims. Adverse changes in relationships with distributors or their financial condition could negatively impact financial results. Work stoppages and labor disputes could affect productivity. Catastrophic events impacting facilities, supply chains, or IT systems could seriously harm operations. Inadequate protection or infringement of intellectual property rights could lead to competitive injury or significant enforcement costs. Restructuring activities, including those related to the Ralliant separation, could have long-term adverse effects on the business. The company is subject to various litigation and legal proceedings, which could result in significant expenses, damages, or reputational harm. Climate change and related regulations may increase costs or disrupt operations. The use of artificial intelligence introduces risks related to accuracy, intellectual property infringement, data privacy, and legal liability. International operations are exposed to economic, political, legal, and compliance factors, trade policy volatility, and foreign currency exchange rate fluctuations. The company's debt levels, approximately $3.2 billion as of December 31, 2025, and rising interest rates could increase debt service obligations and limit financial flexibility. Changes in tax laws, such as the Pillar Two initiative from the OECD, or adverse tax audits could affect profitability. The tax-free status of the Separation Transactions (Danaher, Vontier, Ralliant) could be challenged, leading to significant tax liabilities. Impairment charges for goodwill and other intangible assets, which totaled approximately $9.5 billion as of December 31, 2025, could adversely affect results of operations.

Management Priorities

Management's message to shareholders emphasizes a culture of continuous improvement, embodied in the Fortive Business System (FBS), which is being evolved to incorporate new technology enablers like artificial intelligence and machine learning to drive accelerated innovation, greater commercial success, and more recurring customer value. The company's "Fortive Accelerated" strategy focuses on three pillars: profitable organic growth acceleration, disciplined capital allocation, and building investor trust. Management highlighted that if exchange rates in effect as of December 31, 2025, were to prevail throughout 2026, currency exchange rates would positively impact 2026 estimated sales by approximately 0.8% relative to 2025 performance. Strategic priorities include making significant investments, both organically and through acquisitions, to address technological change and improve manufacturing, R&D, and customer-facing resources. Additionally, management is focused on successfully managing leadership transitions, attracting and retaining key talent, and executing restructuring activities to optimize cost structures, such as the discrete restructuring plan initiated in Q4 2024, which is expected to be completed by the second half of 2026.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Results of Operations
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 8, Consolidated Statements of Earnings
  5. [5] Item 8, Consolidated Statements of Earnings
  6. [6] Item 7, MD&A — Intelligent Operating Solutions Selected Financial Data
  7. [7] Item 7, MD&A — Intelligent Operating Solutions Selected Financial Data
  8. [8] Item 7, MD&A — Intelligent Operating Solutions Selected Financial Data
  9. [9] Item 7, MD&A — Advanced Healthcare Solutions Selected Financial Data
  10. [10] Item 7, MD&A — Advanced Healthcare Solutions Selected Financial Data
  11. [11] Item 7, MD&A — Advanced Healthcare Solutions Selected Financial Data
  12. [12] Item 8, Consolidated Statements of Earnings
  13. [13] Item 8, Consolidated Statements of Earnings
  14. [14] Item 8, Consolidated Statements of Earnings
  15. [15] Item 7, MD&A — Cost of Sales and Gross Profit
  16. [16] Item 8, Consolidated Statements of Earnings
  17. [17] Item 7, MD&A — Operating Profit Margins
  18. [18] Item 8, Consolidated Statements of Earnings
  19. [19] Item 8, Consolidated Statements of Earnings
  20. [20] Item 8, Consolidated Balance Sheets
  21. [21] Item 8, Note 8 — Financing
  22. [22] Item 7, MD&A — Overview of Cash Flows and Liquidity
  23. [23] Item 7, MD&A — Components of Sales Growth
  24. [24] Item 7, MD&A — Components of Sales Growth
  25. [25] Item 7, MD&A — Components of Sales Growth
  26. [26] Item 7, MD&A — Components of Sales Growth
  27. [27] Item 7, MD&A — Operating Profit Margins
  28. [28] Item 7, MD&A — Operating Profit Margins
  29. [29] Item 7, MD&A — Operating Profit Margins
  30. [30] Item 7, MD&A — Intelligent Operating Solutions Components of Sales Growth
  31. [31] Item 7, MD&A — Intelligent Operating Solutions Components of Sales Growth
  32. [32] Item 7, MD&A — Advanced Healthcare Solutions Components of Sales Growth
  33. [33] Item 7, MD&A — Advanced Healthcare Solutions Components of Sales Growth
  34. [34] Item 1, Business — General
  35. [35] Item 7, MD&A — Financing Activities and Indebtedness
  36. [36] Item 7, MD&A — Financing Activities and Indebtedness
  37. [37] Item 7, MD&A — Financing Activities and Indebtedness
  38. [38] Item 8, Note 1 — Acquisitions
  39. [39] Item 7, MD&A — Financial Instruments and Risk Management
  40. [40] Item 8, Note 14 — Share Repurchase Program
  41. [41] Item 8, Note 14 — Share Repurchase Program
  42. [42] Item 8, Note 14 — Common Stock
  43. [43] Item 8, Consolidated Balance Sheets

Analysis on 5/22/2026